Physician profile
Svetlana Zaydman
NPI 1285960013
$3,634.84
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was more than what 76% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.07 · 2020: $281 · 2021: $719 · 2022: $382 · 2023: $67.93 · 2024: $1,792 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Travel and Lodging: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.44 |
| Travel and Lodging | $1,064.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,685.59 | 2024-2025 | Neurostar Tms Therapy System |
| Abbott Laboratories | $697.95 | 2020-2022 | |
| Si-Bone, INC. | $432.79 | 2020-2025 | |
| Medtronic, INC. | $137.72 | 2022 | |
| Electronic Waveform Lab, INC. | $107.03 | 2020 | |
| Indivior INC. | $83.54 | 2019-2025 | Sublocade |
| Bioventus LLC | $80.99 | 2019-2021 | |
| Grt US Holding, INC. | $60.00 | 2022 | |
| Nevro Corp. | $54.14 | 2021-2024 | Senza |
| Fidia Pharma USA INC. | $52.63 | 2024-2025 | Hymovis |
| Lilly USA, LLC | $45.95 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $43.48 | 2021-2025 | |
| Allergan, INC. | $31.16 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $23.75 | 2019 | |
| Mdd US Operations, LLC | $17.62 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $15.04 | 2022 | |
| Amgen INC. | $14.03 | 2022 | |
| Braeburn INC. | $13.79 | 2025 | Brixadi |
| Almatica Pharma LLC | $13.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.59 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Svetlana Zaydman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.